| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Portage Biotech Inc. (NASDAQ:PRTG) on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress.
The new data demonstrate both single-agent activity for PORT-7 and a dramatic >90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine mesothelioma animal model.
Mesothelioma is a rare and aggressive cancer that develops in the thin tissue lining the lungs, abdomen, heart or testicles, strongly linked to asbestos exposure.
Immunohistochemistry of the tumors revealed a significant infiltration of CD3 and CD45 positive immune effector cells.
According to the company, this is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor.
Portage is making preparations to commence a first-in-human clinical trial with PORT-7.
In parallel, Portage is advancing the dose escalation of PORT-6, a potent and selective inhibitor of the A2A adenosine receptor.
Portage’s plan is to ultimately co-administer PORT-6 with PORT-7 in the ongoing ADPORT-601 trial.
This will mark the first time two highly selective A2A and A2B antagonists are combined in patients to achieve a complete blockade of adenosine-induced immunosuppression in the tumor microenvironment.
This innovative approach is designed to fully neutralize adenosine-mediated immune suppression, enhance antitumor responses and broaden the impact of immunotherapy in solid tumors.
In December, Portage and Immunova LLC agreed to negotiate a definitive option agreement for Immunova to acquire Portage's subsidiary, iOx Therapeutics, Ltd.
iOx specializes in developing liposomal iNKT agonists, with its lead candidate, PORT-2, showing encouraging early clinical results.
PRTG Price Action: Portage Biotech stock is up 102.93% at $9.60 at publication Friday.
Read Next:
Photo: Shutterstock
Posted In: PRTG
